3 results match your criteria: "(Dr Ott); and Drucker Brain Injury Center[Affiliation]"
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.
N Engl J Med
April 2016
From the British Heart Foundation Cardiovascular Research Centre (J.J.V.M.) and the Robertson Centre for Biostatistics (N.G.), University of Glasgow, Glasgow, United Kingdom; Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia (H.K.); the Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus (W.T.A.); Stavanger University Hospital, Stavanger, and the Institute of Internal Medicine, University of Bergen, Bergen - both in Norway (K.D.); Rigshospitalet Copenhagen University Hospital, Copenhagen (L.V.K.); the Cardiovascular Division, Brigham and Women's Hospital, Boston (A.S.D., S.D.S.); Novartis Pharma, Basel, Switzerland (M.A.A., Y.C., Q.S., G.T.); and the University of California, San Francisco, San Francisco (B.M.M.).
Background: Among patients with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown. We compared the ACE inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiority) and with the combination of the two treatments (to test superiority) in patients with heart failure and a reduced ejection fraction.
Methods: After a single-blind run-in period, we assigned patients, in a double-blind fashion, to one of three groups: 2336 patients were assigned to receive enalapril at a dose of 5 or 10 mg twice daily, 2340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to receive both treatments (combination therapy).
Predictors of relapse in 300 Brazilian alcoholic patients: a 6-month follow-up study.
Subst Use Misuse
July 2008
Department of Psychiatry and Forensic Medicine, Fundação Faculdade Federal de Ciências Médicas de Porto Alegre, Porto Alegre, RS, Brazil.
Three hundred alcoholic patients were interviewed at hospitalization and again 3 and 6 months thereafter in Porto Alegre, Brazil, from March 2002 to January 2004. Assessment included the SCID-I to check for the presence of Axis I mental disorders, a questionnaire focusing on patient relationship with AA groups, and specific questions about participation in psychotherapy. A logistic regression analysis was performed to determine predictive variables for relapse or abstinence 6 months after discharge.
View Article and Find Full Text PDF